Glenmark USA settles antitrust suits for $29.628 million
Glenmark Pharmaceuticals Limited disclosed that its subsidiary, Glenmark Pharmaceuticals Inc., USA, entered into a settlement agreement to resolve antitrust lawsuits. The subsidiary agreed to pay $29.628 million in annual instalments over five years to settle allegations of price-fixing and market allocation. The company has provided for the full amount in its financials and stated the settlement will not have a significant impact on its financial position.
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals Limited has announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to a settlement agreement to resolve multiple antitrust lawsuits. The disclosure was made to the stock exchanges on May 23, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
The litigation involved allegations of price-fixing, market allocation, and related anti-competitive conduct regarding generic pharmaceutical products. Since 2016, Glenmark USA had been named in more than 35 complaints consolidated in the Eastern District of Pennsylvania, U.S. The plaintiffs included direct purchasers, end-payers, indirect purchasers, and 46 state attorneys general. Three complaints filed by state attorneys general were transferred to the District of Connecticut in 2024.
Settlement Terms
To resolve the dispute and avoid uncertainty, Glenmark USA has agreed to pay a total amount of $29.628 million. The payment will be made in annual instalments over a period of five years. The agreement is subject to approval by the court overseeing the litigation.
| Settlement Detail | Amount / Terms |
|---|---|
| Total Settlement Amount | $29.628 million |
| Payment Structure | Annual instalments over 5 years |
| Status | Subject to court approval |
The company explicitly stated that Glenmark USA denies each and every allegation made against it. The settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of the subsidiary.
Financial Impact
Glenmark Pharmaceuticals Limited confirmed that the full amount of the payments under the settlement agreements has been provided for in its financials. Consequently, the company stated that this settlement will not have a significant impact on its financial position.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.45% | +0.48% | +4.33% | +26.72% | +63.27% | +286.25% |
How will this settlement influence Glenmark's future pricing strategies and compliance protocols for its US generic portfolio?
What are the potential reputational risks for Glenmark when bidding for future US government supply contracts?
Will the cash outflow from the annual instalments affect Glenmark's capacity for R&D investment or capital expenditures over the next five years?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
